Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity
暂无分享,去创建一个
Mary Edson | Robert S. Greenfield | Takushi Kaneko | T. Kaneko | J. Knipe | Gary R. Braslawsky | Kathleen Kadow | Jay Knipe | Kerry McGoff | R. Greenfield | G. Braslawsky | M. Edson | K. Kadow | K. McGoff
[1] R. Webb,et al. Synthesis of 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, novel heterobifunctional cross-linking reagents. , 1990, Bioconjugate chemistry.
[2] R. W. Baldwin,et al. Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates. , 1986, European journal of cell biology.
[3] T. Kaneko,et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. , 1990, Cancer research.
[4] J. Marsh. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin. , 1988, The Journal of biological chemistry.
[5] R. Reisfeld,et al. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[6] I. Witz,et al. Receptors for immune complexes on cells within a polyoma virus‐induced murine sarcoma , 1976, European journal of immunology.
[7] T. Kaneko,et al. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. , 1990, Cancer research.
[8] R. Reisfeld,et al. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[9] R. W. Baldwin,et al. Studies on the mechanism of action of an antibody-targetted drug-carrier conjugate. , 1985, Anti-cancer drug design.
[10] P. Casellas,et al. Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin. , 1985, Experimental cell research.
[11] S. Order,et al. Radiolabeled antibodies: results and potential in cancer therapy. , 1990, Cancer research.
[12] S. Gawlak,et al. Optimization of immunotherapy with adriamycin(hydrazone)-immunoconjugates in human B-lymphoma xenografts , 1991 .
[13] J. Koziol,et al. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. , 1988, Cancer research.
[14] E. Lavie,et al. Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] L. Huang,et al. Interactions of immunoliposomes with target cells. , 1983, The Journal of biological chemistry.
[16] I. Witz,et al. Tumor bound immunoglobulins: The relationship between the in vivo coating of tumor cells by potentially cytotoxic anti‐tumor antibodies, and the expression of immune complex receptors , 1976, International journal of cancer.
[17] F. Preijers,et al. Relationship between internalization and cytotoxicity of ricin A‐chain immunotoxins , 1988, British journal of haematology.
[18] R D Klausner,et al. Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor , 1986, The Journal of cell biology.
[19] I. Witz. The biological significance of tumor-bound immunoglobulins. , 1973, Current topics in microbiology and immunology.
[20] G. Yee,et al. The anticancer agent adriamycin can be actively cytotoxic without entering cells. , 1982, Science.
[21] I. Witz,et al. Receptors for immune complexes on cells within a non-lymphoid murine tumor. , 1976, Journal of immunology.
[22] Mastrangelo Mj,et al. Serotherapy of cancer. , 1989 .
[23] E. Vitetta,et al. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. , 1988, Journal of immunology.
[24] R. W. Baldwin,et al. Preparation and properties of a drug‐carrier‐antibody conjugate showing selective antibody‐directed cytotoxicity in vitro , 1983, International journal of cancer.
[25] Baldwin Rw,et al. Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates. , 1986 .
[26] D. Johnson,et al. Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101. , 1988, Clinical immunology and immunopathology.
[27] R. Steinman,et al. Endocytosis and the recycling of plasma membrane , 1983, The Journal of cell biology.
[28] S. Larson. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. , 1990, Cancer research.
[29] J. Ritz,et al. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. , 1982, Cancer research.
[30] C. Hopkins,et al. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells , 1983, The Journal of cell biology.